Compare AbCellera Biologics Inc (ABCL) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Sibanye Stillwater Ltd — how do they compare? AbCellera Biologics Inc trades at $9.95 (market cap $2.99B), while Sibanye Stillwater Ltd trades at $10.76 (market cap $7.54B). The key difference: Sibanye Stillwater Ltd is far larger — about 2.5× AbCellera Biologics Inc's market cap, and Sibanye Stillwater Ltd pays a 2.93% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | SBSW | |
|---|---|---|
Market Cap | $2.99B | $7.54B |
Sector | Health | Basic Materials |
52-Week High | $9.76 | $21.12 |
52-Week Low | $2.78 | $7.27 |
Enterprise Value | $2.58B | $9.19B |
Dividend Yield | — | 2.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
Sibanye Stillwater (SBSW) trades at $10.67, up 0.28% with a bullish technical signal despite recent earnings misses. The stock shows attractive valuation metrics with P/E of 4.76 and P/S of 0.94, though profitability remains challenged with negative net income margin of -3.99%. Recent news highlights significant price volatility and mixed analyst views on valuation.
The outlook suggests potential upside to the $14.25 consensus price target, supported by projected cash flow improvement in 2025. Key risks include persistent negative earnings, high debt levels, and commodity price sensitivity. Institutional sentiment leans bullish with 43% buy ratings, but investors should monitor execution on debt reduction targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
